BTI Consulting Names Finnegan in its Most Recommended Law Firms 2025 Report

FOR IMMEDIATE RELEASE
April 2, 2025

WASHINGTON, DC—BTI Consulting Group recently published its 2025 Most Recommended Law Firms report, which emphasizes the power of client recommendations in driving law firm growth. The report details which firms receive the highest number of unsolicited, organic peer to peer recommendations and ranks those firms based on size, which firms are winning the recommendations, and across multiple industries. Finnegan is thrilled to be recognized as a Distinguished firm among the most recommended firms and ranked as Highly Recommended among all mid-size firms. Additionally, the report ranked Finnegan as one of the Most Recommended firms for clients seeking a pharmaceutical specialization’ Finnegan is among the top 3% of all firms recommended for pharmaceutical work, regardless of size. According to the report, the Most Recommended pharmaceutical firms are most recommended for their ability to accelerate revenue, reduce risk, and move faster than regulators. Finnegan is especially proud of this ranking, considering the firm’s long history of working with innovative pharmaceutical companies to protect and maximize their IP rights and assets.

With experience addressing virtually every type of IP issue for our pharmaceutical clients, Finnegan is a leader in complex pharmaceutical patent infringement and trade secret cases, including Hatch-Waxman litigation. Since being involved in the very first Abbreviated New Drug Application (ANDA) litigation in the United States, Finnegan has been a leading firm representing innovative pharmaceutical companies before federal district courts and the U.S. Court of Appeals for the Federal Circuit. Our successes derive from a deep bench of experienced and technically sophisticated attorneys who understand the long-term plans of innovative pharmaceutical companies as well as the legal particularities of ANDA litigation under the Hatch-Waxman Act and the nuances of pharmaceutical patent law. Over the last five years, our attorneys have represented 30 brand companies in almost 400 ANDA litigations involving revolutionary drugs such as Prolensa®, Relistor® subcutaneous, Relistor® tablets, Cymbalta®, and Abilify®. 

The BTI Most Recommended Law Firms 2025 report is based on in-depth surveys and telephone interviews with leading legal decision-makers, analyzing trends from over 24,000 corporate counsel client interviews conducted over 23 years. This independent and unbiased research targets top legal decision-makers at large organizations with $1 billion or more in revenue, specifically from industries with high legal expenditures, as well as thought leaders, innovative Chief Legal Officers, Chief Legal Operating Officers, and business executives who influence law firm selection and hiring.

Contacts

Erika H. Arner, Managing Partner
erika.arner@finnegan.com

Anand K. Sharma, Chair
anand.sharma@finnegan.com

About Finnegan
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP is one of the largest IP law firms in the world. From offices in Atlanta, Boston, London, Munich, Palo Alto, Reston, Seoul, Shanghai, Taipei, Tokyo, and Washington, DC, the firm practices European, German, UK, and U.S. IP law. In addition to services related to all aspects of patent, trademark, and copyright law, including counseling, prosecution, licensing, and litigation, Finnegan provides counseling and litigation services in advertising, privacy, and a wide spectrum of additional IP-adjacent commercial matters, including trade secrets, international trade, the Internet, e-commerce, government contracts, antitrust, and unfair competition. For additional information on the firm, please visit www.finnegan.com and follow us on LinkedIn.